Consensus Spero Therapeutics, Inc.

Stocks

SPRO

US84833T1034

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 00:00:00 01/08/2026 +04			5-day change	1st Jan Change
1.170 ^USD	-2.50%		-1.68%	-49.79%

07-27	Spero Therapeutics, Inc. Announces Appointment of Debra Jeske Zack as Chief Medical Officer	CI
07-15	Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion	DJ

Evolution of the Average Target: Spero Therapeutics, Inc.

Evolution of the Target Price: Spero Therapeutics, Inc.

Changes in Analyst Recommendations: Spero Therapeutics, Inc.

504bfd337b4085b11b0fff739.WD7-GqyxineUv39FjfN9mzFH0RqSFkIDdKrzLCGCC_Y.LAmyN_jHshj6iS4V4cAq1hx-tl-_QjtGRN6aHW7rbKUfXMxCxNWnTuDvHA~6f2c7fd687d6d4750a2524942450f49f

Analysts' recommendations: Spero Therapeutics, Inc.

21/10/25	Spero Therapeutics, Inc. and Gsk plc Announces Efficacy and Safety Results of the Positive Pivot-Po Trial Evaluating Tebipenem Hbr	CI
20/12/24	Evercore ISI Downgrades Spero Therapeutics to In Line From Outperform, Price Target is $5	MT
18/11/24	TD Cowen Downgrades Spero Therapeutics to Hold From Buy	MT
06/08/24	TD Cowen Upgrades Spero Therapeutics to Buy From Hold	MT
14/08/23	HC Wainwright Adjusts Price Target on Spero Therapeutics to $7 From $6, Keeps Buy Rating	MT
26/09/22	HC Wainwright Adjusts Spero Therapeutics' Price Target to $6 From $7, Maintains Buy Rating	MT
23/09/22	Evercore ISI Upgrades Spero Therapeutics to Outperform From In-Line	MT
15/08/22	HC Wainwright Adjusts Spero Therapeutics' Price Target to $7 From $10, Keeps Buy Rating	MT
01/07/22	Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	MT
23/05/22	HC Wainwright Adjusts Spero Therapeutics' Price Target to $10 from $37, Keeps Buy Rating	MT
20/05/22	Berenberg Bank Downgrades Spero Therapeutics to Hold From Buy, Adjusts Price Target to $2 From $44	MT
17/05/22	Cantor Fitzgerald Lowers Spero Therapeutics' Price Target to $5 From $27, Overweight Rating Kept	MT
04/05/22	Cowen Downgrades Spero Therapeutics to Market Perform From Outperform	MT
04/05/22	Evercore ISI Downgrades Spero Therapeutics to In-Line From Outperform, Adjusts Price Target to $2 From $40	MT
18/04/22	HC Wainwright Adjusts Spero Therapeutics' Price Target to $37 From $43, Maintains Buy Rating	MT
21/03/22	HC Wainwright Adjusts Spero Therapeutics' Price Target to $43 From $40, Keeps Buy Rating	MT
16/11/21	Berenberg Bank Adjusts Spero Therapeutics PT to $44 From $47, Maintains Buy Rating	MT
01/10/21	SPERO THERAPEUTICS : Oppenheimer Downgrades Spero Therapeutics to Perform from Outperform	MT
12/03/21	SPERO THERAPEUTICS : Oppenheimer Adjusts Spero Therapeutics PT to $20 From $21, Maintains Outperform Rating	MT
22/01/21	SPERO THERAPEUTICS : HC Wainwright Adjusts Spero Therapeutics' Price Target to $40 From $33, Keeps at Buy	MT
05/01/21	SPERO THERAPEUTICS : Oppenheimer Adjusts Spero Therapeutics PT to $21 From $19, Maintains Outperform Rating	MT
16/12/20	SPERO THERAPEUTICS : Berenberg Starts Spero Therapeutics at Buy With $47 Price Target	MT
23/11/20	SPERO THERAPEUTICS : HC Wainwright Adjusts Price Target on Spero Therapeutics to $33 From $28, Reiterates Buy Rating	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
SPERO THERAPEUTICS, INC.	-	-	-	+241.88%
WUXI APPTEC CO., LTD.				+17.16%
ARGENX SE				+20.44%
BIONTECH SE				+34.66%
INSMED INCORPORATED				+98.97%
WUXI BIOLOGICS (CAYMAN) INC.				+21.54%
GENMAB A/S				+28.71%
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.				+17.22%
EXELIXIS, INC.				-1.82%
PHARMAESSENTIA CORPORATION				+1.26%
Average				+48.00%
Weighted average by Cap.				+26.42%